Glaxosmithkline $3 bn Settlement |
ICMR HOME | Case Studies Collection
»Business Ethics Case Studies
Please note: |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abstract:Whistleblowers and the US Justice Department alleged that from 1999 through 2010, GSK was engaged in a fraudulent scheme to deceive and defraud patients, regulators, and federal health programs. The case brings to light the issues and circumstance which led to the lawsuit being filed against GSK and the issues in question in the pharmaceutical industry. The case also brings out the important role played by the whistleblowers in bringing out the unethical practices in the business. Issues:
» To comprehend the business segments of GlaxoSmithKline Contents:
Keywords:Activity Deficit Hyperactivity Disorder (ADHD), Advair, Amerge, American Medical Association, Andrew Witty, Avandia, Cidra Plant, Civil Liabilities, Consumer Healthcare, Corporate Integrity Agreement, Eckard, Emerging Markets, Europe Pharmaceutical and Vaccines, False Claim Act, Food and Drug Administration (FDA), GlaxoSmithKline, Healthcare Fraud, Illegal Market Practices, Imitrex, Lamictal, Medicaid, Off-label promotions, Over-the-counter, Paxil, Pharmaceutical, Pharmaceuticals, Tricare, US Justice Department, US Pharmaceutical and Vaccines, Vaccines, Valtrex, ViiV HealthCare, Wellbutrin, Whistleblower, Zyban
|
Case Studies Links:-
Case Studies,
Short Case Studies,
Simplified Case Studies.
Other Case Studies:-
Multimedia Case Studies,
Cases in Other Languages.
Business Reports Link:-
Business Reports.
Books:-
Textbooks,
Work Books,
Case Study Volumes.